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Immune responseChromosome 3q26–28 is a critical region of genomic ampliﬁcation in non-small cell lung cancer (NSCLC), partic-
ularly lung squamous cell carcinomas (SCCs). No molecular therapeutic target has shown clinical utility for SCC,
in contrast with adenocarcinomas of the lung. To identify novel candidate drivers in this region, we performed
both Array Comparative Genomic Hybridization (array CGH, Agilent Human Genome CGH 244A oligo-microar-
rays) and Gene Expression Microarray (Agilent Human Gene Expression 4 × 44 K microarray) on 24 untreated
lung SCC specimens. Using our previously published integrative genomics approach, we identiﬁed 12 top ampli-
ﬁed driver genes within this region that are highly correlated and overexpressed in lung SCC.We further demon-
strated one of the 12 top ampliﬁed driver Fragile Xmental retardation-related protein 1 (FXR1) as a novel cancer
gene in NSCLC and FXR1 executes its regulatory function by forming a novel complex with two other oncogenes,
protein kinase C, iota ( PRKCI) and epithelial cell transforming 2 (ECT2)within the same amplicon in lung cancer
cell. Here we report that immune response pathways are signiﬁcantly suppressed in lung SCC and negatively as-
sociatedwith 3q driver gene expression, implying a potential role of 3q drivers in cancer immune-surveillance. In
light of the attractive immunotherapy strategy using blockade of negative regulators of T cell function for multi-
ple human cancer including lung SCC, our ﬁndings may provide a rationale for targeting 3q drivers in combina-
tion of immunotherapies for human tumors harboring the 3q amplicon. The data have been deposited in NCBI's
Gene Expression Omnibus and are accessible through GEO Series accession number GSE40089.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(
Speciﬁcationsrganism/cell line/tissue Homo sapiensCx Male and female
quencer or array typeSaAgilent Human Genome CGH 244A oligo-microarrays
and Agilent Human Gene Expression 4 × 44 K
microarrayata format Raw and normalized data were provided
xperimental factors 24 untreated primary lung squamous tumors were
fresh-frozen, with efforts made to use samples with
tumor content N70%.xperimental features Both aCGH and expression microarrays were
performed on the same tumors to identify novel
ampliﬁed driver genes in 3q26–29.ilt-Ingram Cancer Center, 2220
TN 37232-6838, USA. Tel.: +1
assion).
. This is an open access article under thcontinued)
SpeciﬁcationseonsentCC BY-NC-ND license (http:All patients consented before starting the study in
written formmple source location Thoracic Program, Vanderbilt Ingram Cancer Center,
Nashville, TN 37232, USA1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40089.
2. Experimental design, materials and methods
Frozen samples from 24 resected lung squamous carcinomas were
collected from surgical specimens through the Specialized Program of
Research Excellence (SPORE) in the lung at Vanderbilt University//creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Top signiﬁcant functional enrichment of GO biological processes among 194 genes
negatively correlated with 3q meta gene expression.
Biological process (GO term) Number of genes Adjusted p
Immune response 37 7.28E−08
Immune effector process 22 1.35E−06
Immune system process 45 6.09E−06
Regulation of immune response 20 3.00E−04
Activation of immune response 14 5.00E−04
Regulation of immune system process 25 7.00E−04
Defense response 29 7.00E−04
Positive regulation of immune response 15 8.00E−04
Response to stimulus 98 1.20E−03
Leukocyte mediated immunity 11 1.20E−03
273J. Qian et al. / Genomics Data 5 (2015) 272–274Medical Center and the Department of Veterans Affairs (VA) Medical
Center in Nashville, Tennessee. Total DNA or RNA was isolated using
the Qiagen DNeasy Blood & Tissue Kit or RNeasy Kit according to the
manufacturer's instructions (Qiagen, Valencia, CA). Genomic alterations
were determined by aCGH using 244 K CGH oligonucleotide microar-
rays (Hu-244A, Agilent Technologies). Digestion, labeling, and hybridi-
zation were performed at the Vanderbilt Genome Sciences Resource
Core by following Agilent's protocol version 4.0 for Agilent Human Ge-
nome CGH 244A oligo microarrays. The hybridized arrays were washed
and scanned using an Agilent scanner. The array images were then an-
alyzed using Agilent Feature Extraction Software (version 9.5.3.1),
which also performs dye normalization for the data. Then Array CGH
data were analyzed using Agilent DNA Analytics Software (version
4.0) with ADM−2 algorithm, a minimum of three consecutive probes
per region, and a minimum absolute average log2 ratio of 0.25 for any
given region. The average log2 ratio of 0.8 was deﬁned as the cut-off
for ampliﬁcation or 0.3 for low level gain. Genomic positions are
mapped to the hg18 genome build. Evaluation of gene expression was
performed at Vanderbilt Genome Sciences Resource Core using the
Agilent Human Gene Expression 4 × 44 K Microarray platform using
manufacturer-recommended procedures for microarray-based one-
color assay. The arraywas scanned and then analyzed using Agilent Fea-
ture Extraction Software (version 10.7.1.1). The rawdata and associated
sample information were loaded and processed by GeneSpring11
(Agilent Technologies).Fig. 1.mRNA level of the immune system related genes including 14 immune response genes, 11
with 12 3q drive gene expression in 24 lung SCCs. The correlation of indicated gene expressio
Table 1.3. Results
Consistent with the literature, our data conﬁrmed that chromosome
3q is one genomic region that has most prevalent and signiﬁcant copy
number gain in lung SCC [8]. We further identiﬁed a region at 3q26–
28 (182,013,954–186,351,959 bp) containing 370 probes representing
41 genes that have highest ampliﬁcation score (p= 3.12E− 16) across
all 24 samples. Using an integrative genomics approach we previously
published [11], we found that 12 out of 41 3q genes are signiﬁcantly cor-
related in SCCs (ABCC5, ACTL6A, DCUN1D1,MFN1, ZNF639, DVL3, FXR1,
ATP11B, NDUFB5, PIK3CA, DNAJC19 and YEATS2, FDR b 0.05).Whenwe
examined 12 genemRNA levels in TCGA SCC dataset, all of them are sig-
niﬁcantly unregulated in lung SCC (n = 502) compared with normal
lung tissues (n = 51). Notably, all but one novel ampliﬁed 3q gene
YEATS2 were reported as candidate driver gene in our previous studies
[7,11].
To identifymolecular pathways associated with 3q amplicon in lung
SCC, we performed Pearson correlation analysis using 12-gene signa-
ture on 3q chromosome against whole genome expression data obtain-
ed from 24 SCCs. In total we found that 194 gene expressions are
signiﬁcantly negatively correlated with 3q driver gene expression
(FDR b 0.05)while themRNA level of 215 genes is signiﬁcantly positive-
ly correlated with 3q driver gene expression (FDR b 0.05). Gene ontolo-
gy (GO) Enrichment Analysis using negatively correlated 194 genes
revealed that top 10 enriched biological processes are immune response
related (Table 1). In addition,we found that 24 out of 26 immune check-
point genes including CD137, PDCD1 (known as PD-1),HVEM, LAG3,
CD40 and CD27 [1] are also negatively associated with 3q gene expres-
sion (Fig. 1 and Supplementary Table 1).
4. Discussion
Recently, immunotherapy using blockade of negative regulators of T
cell function is an especially attractive approach for multiple human
cancer including lung SCC [6]. Yet there is no deﬁned biomarkers that
can be used asmolecular determinants of response to immunotherapies
such as anti–PD-1 therapy [9]. The 3q ampliﬁcation is considered to be
one of the underlying causes of response to the traditional therapy or
targeted molecular therapy such as anti-PI3K [5]. Here we described a
study combining aCGH and microarray expression on 24 lung SCCs ofinhibitory checkpoint genes and 15 stimulatory checkpoint genes is negatively associated
n to 3q metagene expression and the corresponding p value was listed in Supplementary
274 J. Qian et al. / Genomics Data 5 (2015) 272–274the lung that led to the identiﬁcation of 12 candidate 3q driver genes
including a novel driver gene YEATS2, encoding a scaffolding subunit
of the ADA2A-containing (ATAC) histone acetyltransferase complex
[12], raising the hypothesis that 3q driversmight be involved in the epi-
genetic regulation and metabolism [2]. Moreover, this study revealed a
suppressed immune response pathway in SCC of the lung and its sup-
pression is associatedwith the overexpression of 3q driver gene expres-
sion signature. Being a newly identiﬁed cancer gene in lung cancer [7],
FXR1 encodes an RNA binding protein that controls the expression of
tumor necrosis factor-alpha (TNF-α)[4,10], a keymediator of inﬂamma-
tion in host defense against infection and in autoimmune disease, as
well as several T cell response associated cytokines or chemokines
such as IL-6, CCL2, and CCL5 [3]. Taken together, this work indicates a
potential role of 3q amplicon in the regulation of immune response
and may provide a rationale for targeting 3q driver genes in tumors
harboring the 3q amplicon who might beneﬁt from immune therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2015.06.014.Conﬂict of interest
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